ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial

Song, Yan; Zhang, Bo; Xin, Dao; Kou, Xiaoge; Tan, Zhenbo; Zhang, Shu; Sun, Meili; Zhou, Jin; Fan, Min; Zhang, Ming; Song, Yongxiang; Li, Suyi; Yuan, Yuan; Zhuang, Wu; Zhang, Jingdong; Zhang, Li; Jiang, Hao; Gu, Kangsheng; Ye, Huangyang; Ke, Ying; Li, Jing; Wang, Qingyu; Zhu, Jun; Huang, Jing*复旦大学; 安徽医科大学; 上海交通大学; 厦门大学; 中国医科大学; 中国医学科学院; 重庆大学; 中国医学科学院北京协和医院; 1
Nature Medicine2023-2DOI: 10.1038/s41591-022-02179-2
25被引3阅读
引用收藏
分享

摘要

First-line systemic therapeutic options for advanced esophageal squamous cell carcinoma (ESCC) are limited. In this multicenter, double-blind phase 3 trial, a total of 551 patients with previously untreated, locally advanced or metastatic ESCC and PD-L1 combined positive score of >= 1 were randomized (2:1) to receive serplulimab (an anti-PD-1 antibody; 3 mg/kg) or placebo (on day 1), plus cisplatin (50 mg/m(2)) (on day 1) and continuous infusion of 5-fluorouracil (1,200 mg/m(2)) (on days 1 and 2), once every 2 weeks. The study met the primary endpoints. At the prespecified final analysis of progression-free survival (PFS) assessed by the blinded independent radiological review committee, serplulimab plus chemotherapy significantly improved PFS compared with placebo plus chemotherapy (median PFS of 5.8 months and 5.3 months, respectively; hazard ratio, 0.60; 95% confidence interval, 0.48-0.75; P < 0.0001). At the prespecified interim analysis of overall survival (OS), serplulimab plus chemotherapy also significantly prolonged OS compared with placebo plus chemotherapy (median OS of 15.3 months and 11.8 months, respectively; hazard ratio, 0.68; 95% confidence interval, 0.53-0.87; P = 0.0020). Grade 3 or higher treatment-related adverse events occurred in 201 (53%) and 81 (48%) patients in the serplulimab plus chemotherapy group and the placebo plus chemotherapy group, respectively. Serplulimab plus chemotherapy administered every 2 weeks significantly improved PFS and OS in patients with previously untreated, PD-L1-positive advanced ESCC, with a manageable safety profile. This study is registered with ClinicalTrials.gov (NCT03958890).

学科与关键词

关键词
CANCER5-FLUOROURACILCAMRELIZUMABMULTICENTERCISPLATINSURVIVALTHERAPY
相关
加载中…
  • Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007)
    Huang, Jing; Song, Yan; Kou, Xiaoge; Tan, Zhenbo; Zhang, Shu; Sun, Meili; Zhou, Jin; Fan, Min; Zhang, Ming; Song, Yongxiang; Li, Suyi; Yuan, Yuan; Zhuang, Wu; Zhang, Jingdong; Zhang, Li; Jiang, Hao; Gu, Kangsheng; Ye, Huangyang; Wang, Qingyu; Zhu, JunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
  • First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III study
    Huang, J.; Song, Y.; Kou, X.; Tan, Z.; Zhang, S.; Sun, M.; Zhou, J.; Fan, M.; Zhang, M.; Song, Y.; Li, S.; Yuan, Y.; Zhuang, W.; Zhang, J.; Zhang, L.; Jiang, H.; Gu, K.; Ye, H.; Wang, Q.; Zhu, J.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.被引 1
  • Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
    Wang, Zi-Xian; Cui, Chengxu; Yao, Jun; Zhang, Yanqiao; Li, Mengxia; Feng, Jifeng; Yang, Shujun; Fan, Yun; Shi, Jianhua; Zhang, Xizhi; Shen, Lin; Shu, Yongqian; Wang, Cailian; Dai, Tianyang; Mao, Teng; Chen, Long; Guo, Zengqing; Liu, Bo; Pan, Hongming; Cang, Shundong; Jiang, Yi; Wang, Junye; Ye, Min; Chen, Zhendong; Jiang, Da; Lin, Qin; Ren, Wei; Wang, Junsheng; Wu, Lin; Xu, Yong; Miao, Zhanhui; Sun, Meili; Xie, Conghua; Liu, Ying; Wang, Qifeng; Zhao, Lina; Li, Qi; Huang, Canhong; Jiang, KeCancer Cell, 2022, 40(3): 277-+.被引 139
查看全部 →

发表信息

论文状态
公开发表
期刊
Nature Medicine
发表日期
2023-02
卷期
第 29 卷, 第 2 期
DOI
10.1038/s41591-022-02179-2
语言
ENGLISH
成果收录
SCIE
资助标注
Shanghai Henlius Biotech, Inc.

作者

  • S

    Song, Yan (第一作者)

  • Z

    Zhang, Bo

    chinese acad med sci · peking union med coll

查看全部 24 位作者收起作者
  • X

    Xin, Dao

    chinese acad med sci · peking union med coll

  • K

    Kou, Xiaoge

    1 · xinxiang med univ

  • T

    Tan, Zhenbo

  • Z

    Zhang, Shu

  • S

    Sun, Meili

  • Z

    Zhou, Jin

    sichuan canc hosp

  • F

    Fan, Min

    fudan univ

  • Z

    Zhang, Ming

    shanghai jiao tong univ

  • S

    Song, Yongxiang

  • L

    Li, Suyi

  • Y

    Yuan, Yuan

  • Z

    Zhuang, Wu

    fujian canc hosp

  • Z

    Zhang, Jingdong

    china med univ · liaoning canc hosp & inst

  • Z

    Zhang, Li

    chongqing univ

  • J

    Jiang, Hao

    bengbu med coll

  • G

    Gu, Kangsheng

    1 · anhui med univ

  • Y

    Ye, Huangyang

    1 · xiamen univ

  • K

    Ke, Ying

  • L

    Li, Jing

  • W

    Wang, Qingyu

  • Z

    Zhu, Jun

  • H

    Huang, Jing (通讯)

    chinese acad med sci · peking union med coll

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417